An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results from the DisCoVeRy trial
Abstract Objectives We evaluated the clinical, virological and safety outcomes of lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)-β-1a, hydroxychloroquine or remdesivir in comparison to standard of care (control) in COVID-19 inpatients requiring oxygen and/or ventilatory support. While preliminary results were previously published, we present here the final results, following completion of the data monitoring.Methods We conducted a phase 3 multi-centre open-label, randomized 1:1:1:1:1, adaptive, controlled trial (DisCoVeRy), add-on trial to Solidarity (<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="clintrialgov" xlink:href="NCT04315948">NCT04315948</jats:ext-link>, EudraCT2020-000936-23). The primary outcome was the clinical status at day 15, measured by the WHO 7-point ordinal scale. Secondary outcomes included SARS-CoV-2 quantification in respiratory specimens, pharmacokinetic and safety analyses. We report the results for the lopinavir/ritonavir-containing arms and for the hydroxychloroquine arm, which were stopped prematurely.Results The intention-to-treat population included 593 participants (lopinavir/ritonavir, n=147; lopinavir/ritonavir-IFN-β-1a, n=147; hydroxychloroquine, n=150; control, n=149), among whom 421 (71.0%) were male, the median age was 64 years (IQR, 54-71) and 214 (36.1%) had a severe disease. The day 15 clinical status was not improved with investigational treatments: lopinavir/ritonavir versus control, adjusted odds ratio (aOR) 0.82, (95% confidence interval [CI] 0.54-1.25, P=0.36); lopinavir/ritonavir-IFN-β-1a versus control, aOR 0.69 (95%CI 0.45-1.05, P=0.08); hydroxychloroquine versus control, aOR 0.94 (95%CI 0.62-1.41, P=0.76). No significant effect of investigational treatment was observed on SARS-CoV-2 clearance. Trough plasma concentrations of lopinavir and ritonavir were higher than those expected, while those of hydroxychloroquine were those expected with the dosing regimen. The occurrence of Serious Adverse Events was significantly higher in participants allocated to the lopinavir/ritonavir-containing arms.Conclusion In adults hospitalized for COVID-19, lopinavir/ritonavir, lopinavir/ritonavir-IFN-ß-1a and hydroxychloroquine did not improve the clinical status at day 15, nor SARS-CoV-2 clearance in respiratory tract specimens..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
bioRxiv.org - (2022) vom: 23. Feb. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2022.02.16.22271064 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI035290641 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI035290641 | ||
| 003 | DE-627 | ||
| 005 | 20230429080235.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220222s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.02.16.22271064 |2 doi | |
| 035 | |a (DE-627)XBI035290641 | ||
| 035 | |a (biorXiv)10.1101/2022.02.16.22271064 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Ader, Florence |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results from the DisCoVeRy trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Objectives We evaluated the clinical, virological and safety outcomes of lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)-β-1a, hydroxychloroquine or remdesivir in comparison to standard of care (control) in COVID-19 inpatients requiring oxygen and/or ventilatory support. While preliminary results were previously published, we present here the final results, following completion of the data monitoring.Methods We conducted a phase 3 multi-centre open-label, randomized 1:1:1:1:1, adaptive, controlled trial (DisCoVeRy), add-on trial to Solidarity (<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="clintrialgov" xlink:href="NCT04315948">NCT04315948</jats:ext-link>, EudraCT2020-000936-23). The primary outcome was the clinical status at day 15, measured by the WHO 7-point ordinal scale. Secondary outcomes included SARS-CoV-2 quantification in respiratory specimens, pharmacokinetic and safety analyses. We report the results for the lopinavir/ritonavir-containing arms and for the hydroxychloroquine arm, which were stopped prematurely.Results The intention-to-treat population included 593 participants (lopinavir/ritonavir, n=147; lopinavir/ritonavir-IFN-β-1a, n=147; hydroxychloroquine, n=150; control, n=149), among whom 421 (71.0%) were male, the median age was 64 years (IQR, 54-71) and 214 (36.1%) had a severe disease. The day 15 clinical status was not improved with investigational treatments: lopinavir/ritonavir versus control, adjusted odds ratio (aOR) 0.82, (95% confidence interval [CI] 0.54-1.25, P=0.36); lopinavir/ritonavir-IFN-β-1a versus control, aOR 0.69 (95%CI 0.45-1.05, P=0.08); hydroxychloroquine versus control, aOR 0.94 (95%CI 0.62-1.41, P=0.76). No significant effect of investigational treatment was observed on SARS-CoV-2 clearance. Trough plasma concentrations of lopinavir and ritonavir were higher than those expected, while those of hydroxychloroquine were those expected with the dosing regimen. The occurrence of Serious Adverse Events was significantly higher in participants allocated to the lopinavir/ritonavir-containing arms.Conclusion In adults hospitalized for COVID-19, lopinavir/ritonavir, lopinavir/ritonavir-IFN-ß-1a and hydroxychloroquine did not improve the clinical status at day 15, nor SARS-CoV-2 clearance in respiratory tract specimens. | ||
| 700 | 1 | |a Peiffer-Smadja, Nathan |e verfasserin |4 aut | |
| 700 | 1 | |a Poissy, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Bouscambert-Duchamp, Maude |e verfasserin |4 aut | |
| 700 | 1 | |a Belhadi, Drifa |e verfasserin |4 aut | |
| 700 | 1 | |a Diallo, Alpha |e verfasserin |4 aut | |
| 700 | 1 | |a Delmas, Christelle |e verfasserin |4 aut | |
| 700 | 1 | |a Saillard, Juliette |e verfasserin |4 aut | |
| 700 | 1 | |a Dechanet, Aline |e verfasserin |4 aut | |
| 700 | 1 | |a Mercier, Noémie |e verfasserin |4 aut | |
| 700 | 1 | |a Dupont, Axelle |e verfasserin |4 aut | |
| 700 | 1 | |a Alfaiate, Toni |e verfasserin |4 aut | |
| 700 | 1 | |a Lescure, François-Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Raffi, François |e verfasserin |4 aut | |
| 700 | 1 | |a Goehringer, François |e verfasserin |4 aut | |
| 700 | 1 | |a Kimmoun, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Jaureguiberry, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Reignier, Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Nseir, Saad |e verfasserin |4 aut | |
| 700 | 1 | |a Danion, François |e verfasserin |4 aut | |
| 700 | 1 | |a Clere-Jehl, Raphael |e verfasserin |4 aut | |
| 700 | 1 | |a Bouiller, Kévin |e verfasserin |4 aut | |
| 700 | 1 | |a Navellou, Jean-Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Tolsma, Violaine |e verfasserin |4 aut | |
| 700 | 1 | |a Cabie, André |e verfasserin |4 aut | |
| 700 | 1 | |a Dubost, Clément |e verfasserin |4 aut | |
| 700 | 1 | |a Courjon, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Leroy, Sylvie |e verfasserin |4 aut | |
| 700 | 1 | |a Mootien, Joy |e verfasserin |4 aut | |
| 700 | 1 | |a Gaci, Rostane |e verfasserin |4 aut | |
| 700 | 1 | |a Mourvillier, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Faure, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Pourcher, Valérie |e verfasserin |4 aut | |
| 700 | 1 | |a Gallien, Sébastien |e verfasserin |4 aut | |
| 700 | 1 | |a Launay, Odile |e verfasserin |4 aut | |
| 700 | 1 | |a Lacombe, Karine |e verfasserin |4 aut | |
| 700 | 1 | |a Lanoix, Jean-Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Makinson, Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Martin-Blondel, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Bouadma, Lila |e verfasserin |4 aut | |
| 700 | 1 | |a Botelho-Nevers, Elisabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Gagneux-Brunon, Amandine |e verfasserin |4 aut | |
| 700 | 1 | |a Epaulard, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Piroth, Lionel |e verfasserin |4 aut | |
| 700 | 1 | |a Wallet, Florent |e verfasserin |4 aut | |
| 700 | 1 | |a Richard, Jean-Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Reuter, Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Staub, Thérèse |e verfasserin |4 aut | |
| 700 | 1 | |a Lina, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Noret, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Andrejak, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Lê, Minh Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Peytavin, Gilles |e verfasserin |4 aut | |
| 700 | 1 | |a Hites, Maya |e verfasserin |4 aut | |
| 700 | 1 | |a Costagliola, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Yazdanpanah, Yazdan |e verfasserin |4 aut | |
| 700 | 1 | |a Burdet, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Mentre, France |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2022) vom: 23. Feb. |
| 773 | 1 | 8 | |g year:2022 |g day:23 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.02.16.22271064 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 23 |c 02 | ||
| 953 | |2 045F |a 570 | ||